Citation Tools
PDFRegular and young investigator award abstracts
Novel single-agent immunotherapies
696 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 696 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo